Vectus Biosystems Limited · ASX:VBS
Vectus Biosystems — Shareholder Meeting (October 2026)
10 slides from Vectus Biosystems's shareholder meeting presentation, Oct 28, 2026
Slide 1: Chairman's Address to the 2026 Annual General Meeting
For personal use only Chairman’s Address to the Vectus Biosystems Limited 28 October 2026 Annual General Meeting (AGM) It is my pleasure to provide the Chairman’s address for the 2026 Vectus AGM. Over the past year the Company has revamped its team to support the development and commercialisation of
Slide 2: Chairman's Address conclusion
was completed on 27 May 2026 and in October 2026 the Company received $208,000 from the ATO as its 2025-26 R&D tax offset rebate. Conclusion I thank the Vectus team, the Board and our consultants for their work this year, bringing For personal use only together scientific expertise, clinical insight
Slide 3: CEO's Address for 28 October 2026 AGM
CEO’s Address for 28 October 2026 Annual General Meeting For personal use only Good morning, and thank you for your time today. This is my first AGM as CEO. I started working with Vectus as a consultant in August last year and took on the CEO and CTO role in May 2026. A little about my background. I
Slide 4: What we have done this year
engage with large pharmaceutical companies on potential partnerships. Each step forward, from FDA feedback to an IND to first data in patients, strengthens our position in those discussions. We believe this is how shareholders are best served. What we have done this year For personal use only In Apr
Slide 5: A differentiated approach to pulmonary fibrosis IPF
ASX: VBS al use only Phase 1a Safety Completed Phase 1b/2a Next Value Inflection A differentiated approach to pulmonary fibrosis IPF Lead Indication Annual General Meeting | 28 October 2026 Dr Tara Speranza | CEO & CTO tsperanza@vectusbiosystems.com.au | vectusbiosystems.com.au
Slide 6: Forward-looking statements
Forward-looking statements: This Vectus Biosystems Limited (Vectus or the Company or ASX:VBS) presentation contains forward looking statements that involve risks and uncertainties. It has been prepared for informational purposes only. It does not constitute an offer or invitation to subscribe for, p
Slide 7: The Problem: IPF Facts
AGM 2026 | THE PROBLEM IPF FACTS Idiopathic Pulmonary Fibrosis (IPF): A mostly fatal disease with no cure More common in men over 60 al use only Diagnosis often delayed 1-2 years after symptom Current therapies slow progression, none known to reverse fibrosis. onset Progressive, irreversible lung sc
Slide 8: Building Momentum: 2026 and the Year Ahead
AGM 2026 | OUR PROGRESS Building Momentum: 2026 and the Year Ahead 2026 TO DATE THE YEAR AHEAD al use only May 2026 Jul 2026 Sep 2026 Oct 2026 Mid-Nov 2026 Next 12 months $791,000 placement Cardinal Health FDA grants pre-IND Pre-IND briefing FDA Type B pre-IND IND preparation to advance VB0004 Regul
Slide 9: Our Focus for the Next Twelve Months
AGM 2026 | THE YEAR AHEAD Our Focus for the Next Twelve Months 1 Regulatory 2 Clinical 3 Pipeline al use only • FDA Type B pre-IND meeting • Phase 1b/2a trial, run in Australia, • Library of ~200 related expected by mid-November 2026 in two parts compounds behind VB0004 • FDA feedback will shape the
Slide 10: Get in Touch
GET IN TOUCH Dr Tara Speranza al use only ASX: VBS CEO & CTO Email: info@vectusbiosystems.com.au Web: vectusbiosystems.com.au ASX: VBS
Vectus Biosystems — Shareholder Meeting (October 2026) on 6ix